Hemophagocytic lymphohistiocytosis: A retrospective analysis of 66 patients

被引:0
作者
Thiebaut, L. [1 ]
Pasquier, G. [2 ]
Theret, S. [3 ]
Russello, J. [1 ]
机构
[1] CHU Montpellier, Lab Hematol, 80,Ave Augustin Fliche, F-34090 Montpellier, France
[2] CHU Montpellier, Lab Parasitol Mycol, 39 Ave Charles Flahault, F-34295 Montpellier, France
[3] CHU Montpellier, Pharm Hosp, 80 Ave Augustin Fliche, F-34090 Montpellier, France
来源
REVUE DE MEDECINE INTERNE | 2024年 / 45卷 / 01期
关键词
Hemophagocytic lymphohistiocytosis HLH; Macrophagic activation syndrome MAS; Lymphohistiocytic activation syndrome; PROGNOSTIC-FACTORS; ADULTS; HLH;
D O I
10.1016/j.revmed.2023.10.440
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context. - Hemophagocytic lymphohistiocytosis is a rare syndrome with a poor prognosis, characterized by an uncontrolled dysregulation of the immune system. The rarity of this disease makes it difficult to obtain large cohorts. In this study, we analyzed the data of 66 patients: the objective was to describe the epidemiological, clinical, biological and therapeutic characteristics and to compare our results with those already published. Methods. - We conducted a retrospective study at the University Hospital of Montpellier from 2015 to 2021. Patients were included when the diagnosis of HLH was mentioned on the hospitalization report and when the HSCORE was higher than 50% (169). Prognostic analyses were performed by comparing the patients who died from HMH to those who didn't. Results. - The mean age the 66 patients included was 49.2 years, 62% were men. The percentage of deaths was 45.9%. Lymphoma was the main etiology, followed by infections, then autoimmune/autoinflammatory diseases. Fever, splenomegaly, hepatomegaly and organ failure were the main clinical manifestations. Pancytopenia was present in 62% of cases. Ferritin, triglycerides, LDH and AST were highly increased. Advanced age, associated lymphoma, and the severity of cytopenias were linked to a poor prognosis. Discussion. - The study of the clinico-biological, epidemiological and survival data of the patients in our cohort allowed us to confirm previously published data but also to discuss some of them. (c) 2023 Societe Nationale Franc, aise de Medecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:6 / 12
页数:7
相关论文
共 34 条
[1]   Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide [J].
Arca, Marc ;
Fardet, Laurence ;
Galicier, Lionel ;
Riviere, Sebastien ;
Marzac, Christophe ;
Aumont, Cedric ;
Lambotte, Olivier ;
Coppo, Paul .
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (01) :63-68
[2]   Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation [J].
Baker, KS ;
DeLaat, CA ;
Steinbuch, M ;
Gross, TG ;
Shapiro, RS ;
Loechelt, B ;
Harris, R ;
Filipovich, AH .
BLOOD, 1997, 89 (10) :3857-3863
[3]   Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study [J].
Bergsten, Elisabet ;
Horne, AnnaCarin ;
Arico, Maurizio ;
Astigarraga, Itziar ;
Egeler, R. Maarten ;
Filipovich, Alexandra H. ;
Ishii, Eiichi ;
Janka, Gritta ;
Ladisch, Stephan ;
Lehmberg, Kai ;
McClain, Kenneth L. ;
Minkov, Milen ;
Montgomery, Scott ;
Nanduri, Vasanta ;
Rosso, Diego ;
Henter, Jan-Inge .
BLOOD, 2017, 130 (25) :2728-2738
[4]   Pediatric hemophagocytic lymphohistiocytosis [J].
Canna, Scott W. ;
Marsh, Rebecca A. .
BLOOD, 2020, 135 (16) :1332-1343
[5]   Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry [J].
Cetica, Valentina ;
Sieni, Elena ;
Pende, Daniela ;
Danesino, Cesare ;
De Fusco, Carmen ;
Locatelli, Franco ;
Micalizzi, Concetta ;
Putti, Maria Caterina ;
Biondi, Andrea ;
Fagioli, Franca ;
Moretta, Lorenzo ;
Griffiths, Gillian M. ;
Luzzatto, Lucio ;
Arico, Maurizio .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 137 (01) :188-+
[6]   Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens [J].
Chellapandian, DeepakBabu ;
Das, Rupali ;
Zelley, Kristin ;
Wiener, Susan J. ;
Zhao, Huaqing ;
Teachey, David T. ;
Nichols, Kim E. .
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (03) :376-382
[7]  
Dupuis J, 2004, EMC - Hematol, V1, P135
[8]   Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome [J].
Fardet, Laurence ;
Galicier, Lionel ;
Lambotte, Olivier ;
Marzac, Christophe ;
Aumont, Cedric ;
Chahwan, Doumit ;
Coppo, Paul ;
Hejblum, Gilles .
ARTHRITIS & RHEUMATOLOGY, 2014, 66 (09) :2613-2620
[9]   ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS [J].
FISCHER, A ;
CERFBENSUSSAN, N ;
BLANCHE, S ;
LEDEIST, F ;
BREMARDOURY, C ;
LEVERGER, G ;
SCHAISON, G ;
DURANDY, A ;
GRISCELLI, C .
JOURNAL OF PEDIATRICS, 1986, 108 (02) :267-270
[10]   Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: analysis of 30 cases [J].
Fukaya, S. ;
Yasuda, S. ;
Hashimoto, T. ;
Oku, K. ;
Kataoka, H. ;
Horita, T. ;
Atsumi, T. ;
Koike, T. .
RHEUMATOLOGY, 2008, 47 (11) :1686-1691